Group 1 - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., received a drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [1] - Metoclopramide Hydrochloride Injection is primarily used as an antiemetic for various conditions including chemotherapy, radiotherapy, and postoperative nausea [1] - The drug registration application was submitted in December 2023 and the certificate was obtained in November 2025, with a total R&D investment of approximately 5.9 million yuan [1] Group 2 - The domestic sales figures for Metoclopramide Hydrochloride Injection are projected to be 142 million yuan in 2023 and 118 million yuan in 2024 [2] - The approval of this drug is expected to enhance the company's formulation product portfolio and positively impact its performance in the domestic market [3]

证券代码：600488 证券简称：津药药业 编号：2025-066 三、同类药品市场情况 根据米内网全国放大版的医院数据（含城市公立医院、县级公立医院、城市药 店、网上药店、城市社区医院、乡镇卫生院）显示，盐酸甲氧氯普胺注射液 2023 年、 2024 年国内销售额分别 1.42 亿元、1.18 亿元。 四、影响及风险提示 津药药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司湖北津药药业股份有 限公司（以下简称"湖北津药"）收到国家药品监督管理局核准签发的盐酸甲氧氯 普胺注射液（以下简称 "该药品"或"本品"）的《药品注册证书》。现将相关情况公 告如下： 1 / 2 药品名称 盐酸甲氧氯普胺注射液 剂型 注射剂 注册分类 化学药品 3 类 药品注册标准编号 YBH25362025 规格 2ml:10mg（按 C₁₄H₂₂ClN₃O₂•HCl 计） 受理号 CYHS2303377 证书编号 2025S03273 药品批准 ...

Core Viewpoint - The company, Tianyao Pharmaceutical (600488.SH), announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [1] Group 1 - The approved drug, Metoclopramide Hydrochloride Injection, is primarily used as an antiemetic for various conditions including chemotherapy, radiotherapy, surgery, and brain injuries [1] - The medication is indicated for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic disorders, and uremia [1] - It also aids in facilitating duodenal intubation prior to diagnostic procedures and helps reduce nausea and vomiting during gastrointestinal barium X-ray examinations [1]

Core Viewpoint - Tianyao Pharmaceutical (600488) announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for a key product in its portfolio [1] Company Summary - Tianyao Pharmaceutical's subsidiary has been granted approval for Metoclopramide Hydrochloride Injection, which is primarily used as an antiemetic [1] - The injection is indicated for various conditions including chemotherapy, radiotherapy, surgery, and other medical situations that may cause nausea and vomiting [1] - The product also aids in diagnostic procedures such as duodenal intubation and enhances the passage of barium during gastrointestinal X-ray examinations [1] Industry Summary - The approval of Metoclopramide Hydrochloride Injection highlights the ongoing demand for antiemetic medications in the healthcare sector, particularly in oncology and gastroenterology [1] - This development may enhance the competitive positioning of Tianyao Pharmaceutical within the pharmaceutical industry, especially in the antiemetic market segment [1]

Core Viewpoint - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Methoclopramide Hydrochloride Injection, which is expected to positively impact the company's performance and market expansion in the domestic formulation sector [1] Group 1 - The approved drug is classified as a Class 3 chemical drug and has passed the consistency evaluation of quality and efficacy for generic drugs [1] - The approval enhances the company's formulation product portfolio, which is anticipated to contribute positively to the company's performance [1] - The development, production, and sales of pharmaceuticals are subject to significant uncertainties due to national policies and market conditions [1]

Core Viewpoint - The company, Tianyao Pharmaceutical (600488.SH), announced that its subsidiary, Hubei Tianyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [1] Group 1: Product Information - Metoclopramide Hydrochloride Injection is an antiemetic drug primarily used for nausea and vomiting caused by chemotherapy, radiotherapy, surgery, and other medical conditions [1] - The drug is also indicated for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic disorders, and uremia [1] - Additionally, it aids in facilitating duodenal intubation and reduces nausea and vomiting during gastrointestinal barium X-ray examinations [1]

Core Viewpoint - The company has received approval for the drug Methochlorpromazine Hydrochloride Injection, which is primarily used as an antiemetic for various medical conditions [1] Group 1: Product Approval - The subsidiary Hubei Jinyao Pharmaceutical Co., Ltd. has obtained the Drug Registration Certificate from the National Medical Products Administration for Methochlorpromazine Hydrochloride Injection [1] - This injection is indicated for use in chemotherapy, radiotherapy, surgery, and conditions such as brain injuries and drug-induced vomiting [1] Group 2: Medical Applications - Methochlorpromazine Hydrochloride Injection is used for symptomatic treatment of nausea and vomiting associated with acute gastroenteritis, biliary and pancreatic diseases, and uremia [1] - It aids in diagnostic procedures such as duodenal intubation and reduces nausea during gastrointestinal barium X-ray examinations [1]

Core Viewpoint - Tianyao Pharmaceutical stated that as of October 31, 2025, the number of shareholders will be 38,934 [2] Summary by Category - Company Information - Tianyao Pharmaceutical has confirmed the projected number of shareholders to be 38,934 by the end of October 2025 [2]

Group 1 - Jinguang Electric won a bid for a State Grid procurement project with a total amount of 21.7976 million yuan, accounting for approximately 2.93% of the company's expected revenue for 2024 [1] - Shen Gong Co. plans to reduce its shareholding by up to 2%, equating to 340.61 million shares [2] - Guomai Culture received a government subsidy of 3.78 million yuan, representing 24.90% of its audited net profit for 2024 [2] Group 2 - Guomai Culture focuses on the development and provision of digital content operation platforms [3] - Shentong Technology's two directors plan to collectively reduce their shareholding by no more than 0.0473% [4] - Ruihua Tai intends to reduce its shareholding by up to 1%, amounting to 1.8 million shares [5] Group 3 - Guoji Automobile's wholly-owned subsidiary won a total contract project worth 809 million yuan [7] - Changcheng Technology's stock is expected to remain suspended due to potential changes in control [9] - Huabei Pharmaceutical's subsidiary received approval for a chemical raw material drug listing application [11] Group 4 - Fuyao Glass has changed its legal representative to Cao Hui [13] - Huaxi Biological plans to reduce its shareholding by up to 2%, totaling 9.6336 million shares [14] - Hopu Co. signed a procurement contract for a storage system worth 500 million yuan [15] Group 5 - ST Songfa's subsidiary plans to invest 458 million yuan in a mooring dock project [18] - Zhonghong Medical's subsidiary is expected to be selected for several centralized procurement projects [19] - Huakai Yibai's vice chairman plans to increase his shareholding by no less than 30 million yuan [20] Group 6 - Haichuang Pharmaceutical completed the first participant enrollment for a clinical trial of a drug for metabolic-associated fatty liver disease [21] - Dongfang Biological's subsidiary obtained medical device product registration certificates for multiple products [22] - Lepu Medical's rechargeable implantable deep brain stimulation system received NMPA registration approval [23] Group 7 - Changyuan Power's power generation in October decreased by 32.25% year-on-year [24] - Jinshi Yaya's diclofenac sodium sustained-release tablets passed the consistency evaluation for generic drugs [26] - Yutong Bus sold 3,040 buses in October, a decrease of 5.62% year-on-year [27] Group 8 - Far East Co. signed contracts worth 1.062 billion yuan in October [28] - Tianya Pharmaceutical's subsidiary passed the consistency evaluation for a drug [29] - Yuheng Pharmaceutical plans to resolve a debt dispute through a share transfer agreement [30] Group 9 - Hailanxin's subsidiary won a bid for a marine observation network project worth 1.097 billion yuan [31] - Huasheng Lithium plans to reduce its shareholding by up to 0.37% [33] - Maike Biological obtained product registration certificates for five new in vitro diagnostic products [34] Group 10 - Huayuan New Materials signed a strategic cooperation agreement with Taiblue New Energy [37] - Greebo's actual controller and some directors plan to collectively increase their shareholding by no less than 11.5 million yuan [39] - Yian Technology received a government subsidy of 1.1643 million yuan [41] Group 11 - Kangtai Biological's quadrivalent influenza virus vaccine has commenced Phase I clinical trials [43] - Spring Airlines received a commitment letter for a stock repurchase loan of up to 450 million yuan [45] - Foton Motor sold 8,006 new energy vehicles in October, a year-on-year increase of 98.83% [46] Group 12 - Greebo plans to transfer 100% equity of its subsidiary for 280 million yuan [48] - Siwei Liekong's director is under investigation [49] - Dingyang Technology launched a new generation of multi-channel microwave signal generator products [50] Group 13 - Jiangling Motors reported a year-on-year increase of 8.06% in vehicle sales for October [51] - Shengyi Technology plans to reduce its shareholding by up to 1.03% [52] - Dongshan Precision completed the acquisition of 100% equity of France's GMD Group for approximately 814 million yuan [53] Group 14 - Tianyang Technology plans to acquire 7.5% of Baoland's shares for 155 million yuan [54] - Alter plans to establish a joint venture company with a total investment of 672 million yuan [54] - Changchun High-tech's clinical trial application for a drug was approved [55] Group 15 - Beibu Gulf Port's cargo throughput in October increased by 22.73% year-on-year [56] - ST Zhangjiajie was ruled by the court to undergo reorganization [57] - Teda Co.'s subsidiary was selected as a supplier for an energy project in Indonesia [58]

证券代码：600488 证券简称：津药药业 编号：2025-065 津药药业股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司津药和平（天津）制药有 限公司（以下简称"津药和平"）收到国家药品监督管理局核准签发的复合磷酸氢钾注射 液（以下简称 "该药品"或"本品"）的《药品补充申请批准通知书》，批准本品通过 仿制药质量和疗效一致性评价（以下简称"一致性评价"）。现将相关情况公告如下： | 药品名称 | 复合磷酸氢钾注射液 | | --- | --- | | 剂型 | 注射剂 | | 注册分类 | 化学药品 | | 药品注册标准编号 | YBH28942025 | | 规格 | 和磷酸氢二钾（按 2ml:磷酸二氢钾 0.448g K2HPO4计）0.472g | | 受理号 | CYHB2450387 | | 通知书编号 | 2025B05109 | | 原药品批准文号 | 国药准字 H10980220 | | 申请内 ...